Brodalumab

Identification

Name
Brodalumab
Accession Number
DB11776
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
AMG 827 / AMG-827 / KHK-4827 / KHK4827
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SiliqInjection210 mg/1SubcutaneousValeant Pharmaceuticals North America2017-02-15Not applicableUs
Categories
UNII
6ZA31Y954Z
CAS number
1174395-19-7

Pharmacology

Indication

Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Structured Indications
Pharmacodynamics

Increase in the level of IL-17 due to blocking of its receptors.

Mechanism of action

Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Absorption
Not Available
Volume of distribution

4.62 L.

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance

0.223 L/day.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Brodalumab.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brodalumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brodalumab.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Brodalumab.Approved
FingolimodBrodalumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Brodalumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Brodalumab.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Brodalumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Brodalumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Brodalumab is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Brodalumab.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brodalumab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Brodalumab.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Brodalumab.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Brodalumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Brodalumab.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brodalumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Brodalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Brodalumab.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Brodalumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Brodalumab.Investigational
TofacitinibBrodalumab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Brodalumab.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Brodalumab.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Brodalumab.Approved
Food Interactions
Not Available

References

General References
  1. article [Link]
  2. article [Link]
External Links
KEGG Drug
D10061
Wikipedia
Brodalumab
ATC Codes
L04AC12 — Brodalumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailablePsoriasis1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPsoriasis2
1WithdrawnBasic ScienceAsthma Bronchial1
1, 2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentModerate to Severe Plaque Psoriasis1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentCrohn's Disease (CD)2
2TerminatedTreatmentPsoriasis1
2TerminatedTreatmentPsoriatic Arthritis1
2TerminatedTreatmentRheumatoid Arthritis1
2WithdrawnTreatmentSpondyloarthritis, Axial1
3Active Not RecruitingTreatmentModerate to Severe Plaque Psoriasis1
3CompletedTreatmentPsoriasis2
3CompletedTreatmentPsoriasis Vulgaris / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular Psoriasis / Pustular; Psoriasis, Palmaris Et Plantaris1
3CompletedTreatmentPsoriatic Arthritis1
3RecruitingTreatmentSpondyloarthritis, Axial1
3TerminatedTreatmentModerate to Severe Plaque Psoriasis3
3TerminatedTreatmentPsoriasis1
3TerminatedTreatmentPsoriatic Arthritis1
Not AvailableNot Yet RecruitingNot AvailablePsoriasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous210 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:47 / Updated on March 08, 2017 14:30